During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be ...

Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment. The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was ...

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.

Truist Securities adjusted its outlook for Sangamo BioSciences, reducing the price target on the company's shares to $5 from ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $26.01. According to ...

Get Our Latest Stock Analysis on PFE Pfizer Trading Down 0.7 % Shares of PFE stock opened at $26.30 on Monday. The stock has a market cap of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of ...

Pfizer Trading Down 0.7 % Shares of PFE opened at $26.30 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low ...

Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm ...